GB1 / Denali Therap - LARVOL DELTA

IDENTIFICATION OF GCASE ACTIVITY MODIFIERS TO ELUCIDATE GENETIC DRIVERS OF PARKINSON'S DISEASE (ADPD 2026) - "Taken together, our work uncovers genetic modulators of GCase activity, providing a framework to investigate how these genes may influence the penetrance of GBA1 mutations and contribute to genetically-driven reductions in GCase activity in sPD."

CNS Disorders • Movement Disorders • Parkinson's Disease • GBA • GBA1

DYSREGULATION OF LYSOSOMAL AND AUTOPHAGIC-ASSOCIATED PROTEINS IN PBMCS AND PLASMA FROM PARKINSON'S DISEASE PATIENTS (ADPD 2024) - "Reduced LAMP1 levels in PD patient supports the hypothesis that lysosomes are reduced in PD patients. Additionally, elevated CatB levels in plasma suggests dysregulation in the normal lysosomal pathway in PD patients. We confirmed prior reports of elevated GCase activity in LRRK2 carriers, which may be biologically meaningful considering reduction of GlcSph."

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease • CTSB • GBA • LAMP1 • LRRK2